p53 codon 72 polymorphism and risk of cervical cancer in UK

Lancet

Volumn 352, Issue 9131, 1998, Pages 871-872

  Rosenthal, Adam N ^a   Ryan, Andy ^a   Al Jehani, Rajai M ^a   Storey, Alan ^a   Harwood, Catherine A ^a   Jacobs, Ian J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ARTICLE; BLOOD SAMPLING; CANCER RISK; CODON; DNA POLYMORPHISM; ETHNIC GROUP; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA TRANSLATION; TUMOR SUPPRESSOR GENE; UNITED KINGDOM; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0032511551     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07357-7     Document Type: Article

References (5)

1. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-34.
2. Beckman G, Birgander R, Sjalander A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44: 266-70.
3. Samsbrook J, Fritsch EF, Maniatis T. Molecular cloning, 2nd edn. New York: Cold Spring Harbour Laboratory Press, 1989.
4. de la Calle-Martin O, Fabregat V, Romero M, Soler J, Vives J, Yague J. AccII polymorphism of the p53 gene. Nucl Acid Res 1990; 18: 4963.
5. Kaelbling M, Burk R, Atkin NB, Johnson AB, Klinger HP. Loss of heterozygosity on chromosome 17p and mutant p53 in HPV-negative cervical carcinomas. Lancet 1992; 340: 140-42.